THE RESULTS OF THE ANALYSIS OF THE EFFECTIVENESS OF THE APPOINTMENT OF RALTEGRAVIR FOURTH DRUG IN THE SCHEME OF PMR PREGNANT WOMEN WHO HAVE A DETERMINED LEVEL OF VIRAL LOAD AT 28-32 WEEKS OF PREGNANCY
Raltegravir is a drug belonging to the group of integrase inhibitors, which are currently widely used in the territory of the Russian Federation, as part of the first-line therapy regimens. Particular attention is paid to the use of raltegravir in art regimens prescribed to pregnant women. The use of raltegravir in art regimens approved for use in pregnant women in the Russian Federation is regulated by the clinical guidelines "HIV infection: Prevention of perinatal transmission of the human immunodeficiency virus" (2017). This article presents the results of a study on the validity and effectiveness of raltegravir fourth drug in art regimens to prevent mother-to-child transmission of HIV to pregnant women, late to the dispensary, or having a detectable viral load at 28-32 weeks, in order to reduce the risk of perinatal transmission of HIV from mother to child.